Industry Briefs: December 3, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: December 3, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI will close its Bothell, Washington, site, and transition the site’s drug-discovery capabilities to Singapore while certain analytical capabilities will consolidate into the company’s analytical quality group in Albany, New York. Read More

Aptiv Solutions has opened a new laboratory and office in Durham, North Carolina. Read More

Bend Research, PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) have developed a new technology for the production of thermostable vaccines. Read More

biOasis Technologies has entered into a research collaboration agreement with UCB to evaluate biOasis’s Transcend technology in the area of the delivery of therapeutic compounds to the brain. Read More

Capsugel has doubled its laboratory capacity with the opening of its new quality-control laboratory in Greenwood, South Carolina. Read More

Covance’s early-development facility in Shanghai, China, has received a Good Laboratory Practice Certificate from China’s State Food and Drug Administration. Read More

Dalton Pharma Services has added size-exclusion chromatography (SEC) - multi angle (laser) light-scattering (MALS) large-molecule testing services. Read More

Galena Biopharma has signed an agreement with a subsidiary of Teva Pharmaceutical Industries for the commercialization of NeuVax (nelipepimut-S or E75) in Israel. Read More

Hovione and Solvias have announced a collaboration focused on the development and GMP supply of pharmaceutical cocrystals. Read More

NextPharma has completed the sale of its Bioserv, its US affiliate, to KESA Partners. Read More

Noven Pharmaceuticals has acquired commercial rights to Minivelle (estradiol transdermal system) in the US and Canada. Read More

Recipharm has invested to expand its capacity in analytical services and stability studies at its facility in Solna, Sweden. Read More

Single Cell Technology and Open Monoclonal Technology have announced a human antibody discovery and development collaboration. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here